266 related articles for article (PubMed ID: 35112998)
1. "
Checkley L; Steiger S; Knight KR
Subst Abus; 2022; 43(1):767-773. PubMed ID: 35112998
[No Abstract] [Full Text] [Related]
2. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
[TBL] [Abstract][Full Text] [Related]
3. Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule.
Laks J; Kehoe J; Farrell NM; Komaromy M; Kolodziej J; Walley AY; Taylor JL
Addict Sci Clin Pract; 2021 Dec; 16(1):73. PubMed ID: 34961554
[TBL] [Abstract][Full Text] [Related]
4. Loss, liberation, and agency: Patient experiences of methadone treatment at opioid treatment programs during the COVID-19 pandemic.
López-Castro T; Jakubowski A; Masyukova M; Peterson M; Pierz A; Kodali S; Arnsten JH; Starrels JL; Nahvi S
J Subst Use Addict Treat; 2024 Feb; 157():209235. PubMed ID: 38061636
[TBL] [Abstract][Full Text] [Related]
5. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
[No Abstract] [Full Text] [Related]
6. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
7. Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system.
Gryczynski J; Jaffe JH; Schwartz RP; Dušek KA; Gugsa N; Monroe CL; O'Grady KE; Olsen YK; Mitchell SG
Am J Addict; 2013; 22(3):285-91. PubMed ID: 23617873
[TBL] [Abstract][Full Text] [Related]
8. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
Bishop B; Gilmour J; Deering D
Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and current clinical practices of opioid treatment programs in the United States.
Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
[TBL] [Abstract][Full Text] [Related]
10. Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.
Neale J; Tompkins CNE; Strang J
Drug Alcohol Rev; 2019 Jul; 38(5):510-518. PubMed ID: 31131514
[TBL] [Abstract][Full Text] [Related]
11. Novel Uses of Methadone Under the "72-Hour Rule" to Facilitate Transitions of Care and Low-Dose Buprenorphine Induction in an Outpatient Bridge Clinic.
Shahlapour M; Singh S; Christine PJ; Laks J; Evans J; Farrell NM; Khan GK; Taylor JL; Rozansky H
J Addict Med; 2024 May-Jun 01; 18(3):345-347. PubMed ID: 38329815
[TBL] [Abstract][Full Text] [Related]
12. Medications for management of opioid use disorder.
Koehl JL; Zimmerman DE; Bridgeman PJ
Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
[TBL] [Abstract][Full Text] [Related]
13. Relationship between choice of opioid agonist therapy and distance from patients' residences in Taiwan, 2012-2014.
Wei LC; Chan HY
Am J Drug Alcohol Abuse; 2021 Sep; 47(5):590-598. PubMed ID: 34402338
[TBL] [Abstract][Full Text] [Related]
14. "Get in and get out, get on with life": Patient and provider perspectives on methadone van implementation for opioid use disorder treatment.
Suen LW; Steiger S; Shapiro B; Castellanos S; Joshi N; Lambdin BH; Knight KR
Int J Drug Policy; 2023 Nov; 121():104214. PubMed ID: 37778132
[TBL] [Abstract][Full Text] [Related]
15. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
[TBL] [Abstract][Full Text] [Related]
16. "Just give them a choice": Patients' perspectives on starting medications for opioid use disorder in the ED.
Schoenfeld EM; Westafer LM; Beck SA; Potee BG; Vysetty S; Simon C; Tozloski JM; Girardin AL; Soares WE
Acad Emerg Med; 2022 Aug; 29(8):928-943. PubMed ID: 35426962
[TBL] [Abstract][Full Text] [Related]
17. Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers.
Calcaterra SL; Lockhart S; Callister C; Hoover K; Binswanger IA
J Gen Intern Med; 2022 Aug; 37(11):2786-2794. PubMed ID: 34981359
[TBL] [Abstract][Full Text] [Related]
18. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
[TBL] [Abstract][Full Text] [Related]
19. Transitioning off methadone: A qualitative study exploring why patients discontinue methadone treatment for opioid use disorder.
Thakrar AP; Pytell JD; Stoller KB; Walters V; Weiss RD; Chander G
J Subst Use Addict Treat; 2023 Jul; 150():209055. PubMed ID: 37088398
[TBL] [Abstract][Full Text] [Related]
20. METHADONE INITIATION IN THE EMERGENCY DEPARTMENT FOR OPIOID USE DISORDER: A CASE SERIES.
Huo S; Heil J; Salzman MS; Carroll G; Haroz R
J Emerg Med; 2023 Mar; 64(3):391-396. PubMed ID: 37019500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
